MaxCyte, Inc.

Discovery is only the beginning, and your pathway into development should be a smooth one. With the ExPERT DTx™ , optimized protocols transfer directly across the ExPERT platform — enabling scale-up and cGMP-compliant manufacturing without reoptimization. Bench-to-clinic continuity isn’t optional. It’s essential. See how we scale (link in comments).

We’re looking forward to seeing you tomorrow at the next stop on the 2026 G-Rex® Grant Tour - San Francisco! 📍 Forum at Gateway of Pacific 📅 March 27, 2026 | 10:00 AM – 7:00 PM 📍 San Francisco, CA Stop by our table and say hello to Angel, Stephano and Struan, who will be on site to connect throughout the day. 👉 Registration is still open — details and sign-up link in the comments.

Join us on April 9th to explore what it takes to move gene-edited therapies toward commercialization. Our Field Application Scientist, Linda Meggiolaro, will be presenting at the Cell & Gene virtual expo on how developers can approach genotoxicity assessment with confidence, a critical step in achieving regulatory readiness for gene-edited cell and gene therapies. In this session, she will highlight how the MaxCyte® SeQure™ platform supports comprehensive risk evaluation through a combination of variant-aware screening and orthogonal biochemical and cell-based assays. These approaches enable detection of on- and off-target events across diverse genomic contexts. Together, these methods provide the depth of insight needed to advance therapies safely and efficiently toward clinical and commercial success. If you are focused on gene editing, safety, and regulatory strategy, this is a session you will not want to miss. Register via the link in comments! 👇 #SeQure #cgt #commercialization

We’re pleased to welcome Parmeet Ahuja as Chief Financial Officer at MaxCyte. Parmeet brings more than 20 years of finance leadership experience across a global, publicly traded life sciences organization, most recently serving as Vice President of Investor Relations at Agilent Technologies. His background spans financial operations, strategic FP&A, and investor relations. We’re excited to have Parmeet join the team as we continue to strengthen our financial foundation and support the next phase of growth at MaxCyte. Welcome to the team, Parmeet Ahuja!

We’re excited to be at CRISPR Down Under 2026 in Melbourne with TrendBio Pty Ltd! This meeting brings together researchers and innovators advancing genome editing across research and therapeutic development, and we’re looking forward to being part of the conversation. 📍 Melbourne, Australia 📅 24–25 March 2026 We’ll be presenting a poster on a variant-aware approach to reducing off-target risk in therapeutic guide RNA selection. If you’re attending, let’s connect!

Collaboration starts with conversation and the right scientific alignment. Our team recently visited CTMC to explore opportunities to advance cell therapy development together. Their integrated approach, from process development through clinical manufacturing, plays a critical role in moving therapies forward. At MaxCyte, we’re focused on enabling scalable, efficient cell engineering through our electroporation platform, and engaging with teams like CTMC is how progress begins. Thank you to the CTMC team for the thoughtful discussion. #CellTherapy #Biotech #Innovation

Why do these viability curves start to diverge after day 8—and why does it matter? 👀 In this study, Genentech engineered apoptosis-resistant producer cell lines to better tolerate the stress of protein production under intensified conditions. The key question was whether those engineered cells could perform as stable bulk pools at scale. Using MaxCyte's electroporation technology, expression plasmids for a bispecific antibody and two complex biologics were delivered into the knockout CHO lines to generate stable pools. Those knockout pools: - Maintained high viability well beyond the point where wild-type cell line viability declined - Produced at high titers, with day 14 titers exceeding 8 g/L for some pools - Demonstrated that Genentech’s host-cell engineering strategy held up under real-world production conditions 🔗 Explore the full data and figures (link in comments).

In high-throughput screening, reproducibility is essential. The ExPERT™ DTx processes up to 96 samples in a single 3-minute run with consistent well-to-well performance, eliminating transfection as an experimental variable. Reproducible. Controlled. Built for serious discovery programs. Find out more (link in comments).

🎉 We’re honored to be recognized by the Maryland Tech Council as finalists for the 2026 ICON Awards. MaxCyte has been named a finalist for Life Sciences Company of the Year, and our President & CEO, Maher Masoud, has been named a finalist for Life Sciences CEO of the Year. The ICON Awards celebrate the leaders and companies driving innovation across Maryland’s technology and life sciences ecosystem. We’re proud to be part of a community advancing the next generation of transformative therapies. Congratulations to all the finalists—we look forward to celebrating with you. For the full list of nominees, see link in comments 👇 . #CellTherapy #GeneTherapy #Biotech #Innovation #ICONAwards

Catch up with us at the Innate Killer Summit! We’ll be at Booth 1. This meeting brings together the global NK cell therapy community to discuss advances in engineering strategies, persistence, targeting, and clinical translation of innate immune cell therapies. 📍 San Diego, CA 📅 23–25 March 2026 📌 Booth 1 Stop by to connect with Brian LaPutka, Angel Galarza, and Michelle Duong. Looking forward to the conversations ahead.